HEMATO-BIO-IPC-2013-015 is a monocenter prospective longitudinal study. Our aim is to define predictive clinical and biological factors in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by using genomics, genetics and epigenetics, in vitro and in vivo drug sensitivity studies,and translational immonulogy and immunomonitoring studies. HEMATO-BIO primary outcome measure is to identify molecular, genomic and epigenetic, pharmacologic and immunophenotypic alteration in acute leukemia, myelodysplastic syndromes and myeloproliferative disorders by collecting, at diagnosis and/or complete remission and/or relapse: * tumor samples: marrow aspiration, blood sampling. * non-tumor samples: skin biopsy, buccal swab . from 650 patients treated at our cancer center.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
650
Longitudinal (3 stages of the disease)
Longitudinal (3 stages of the disease)
Single biopsy (optional)
Single sampling.
Institut Paoli-Calmettes
Marseille, France
Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)
Time frame: up to 8 years
Correlation between molecular alteration and clinical characteristics(diagnosis,cytogenetics,overall survival, progression free survival)
Time frame: up to 8 years
Compare cancer and non-tumor cells genome
Time frame: up to 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.